Antiplatelet agents play an important role in the treatment of ACS.
因此抗血小板药物在ACS治疗中有着重要的地位。
There is currently no robust evidence to support the use of venous antiplatelet agents.
目前尚无足够的证据推荐使用静脉抗血小板制剂。
There is no evidence that antiplatelet agents reduce atherosclerotic risk in patients with HF.
没有任何证据表明，抗血小板制剂降低心衰患者动脉粥样硬化的危险。
应用推荐